Our Latest News
Projects 02/02/2012
The European Patients' Academy on Therapeutic Innovation (EUPATI)
European Patients' Academy on Therapeutic Innovation (EUPATI). launched on 1st February 2012.
Upcoming events 23/01/2012
Risk Talk on HIV - insuring the uninsurable - Join the live webcast for the Risk Talk today at 18:00 CET
"We are going to win this fight." President Barack Obama declared on 1 December 2011, World AIDS Day. The prospect of "an Aids-free generation" was unimaginable just a short while ago.
Correlation Network II 12/01/2012
Correlation Network II
Report of the final Conference of Correlation Network II "Getting out of the margins – changing realities and making the difference"
12-14 December, Ljubljana, Slovenia
Correlation Network II 12/01/2012
New Policy Recommendations for Vulnerable Populations
The prevalence of HIV/AIDS and other blood-borne infectious diseases is known to be high in vulnerable populations. Concerned about a resurgent HIV epidemic concentrated among key populations in the European Union (EU) and European Free Trade Area countries (EFTA)
Vacancies 12/01/2012
Volunteer - European Voluntary Service (EVS)
The EATG is looking for a volunteer to support us with our communication work towards people living with HIV/AIDS and other stakeholders. The volunteer would be involved in projects to raise awareness about HIV in Europe, mainly among young communities.
Upcoming events 09/01/2012
HIV 30 years on - the impact on society and the insurance industry
26 - 27 January 2012, event organised by the Swiss Re Insurance Company Ltd. and Aids-Hilfe Schweiz
About us 15/12/2011
Contact us
Our office will be closed from December 24th until January 8th 2011. We wish you Happy Holidays and a Happy New Year!
Newsletters 13/12/2011
Parliamentary Magazine - Special Edition - World AIDS Day, 1st December 2011
A Parliament Magazine Special Supplement on HIV and AIDS, with contribution from the EATG and HIV in Europe
Global HIV News
Prevention 03/02/2012
Africa: No time to 'give up' on HIV-fighting gel
Researchers are optimistic that they are learning as much from their failures as their successes.
Hepatitis 03/02/2012
Idenix announces removal of the partial clinical hold on HCV nucleotide inhibitor, IDX184
The Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin may continue.
Tuberculosis & Malaria 03/02/2012
Global malaria deaths twice as high as previously estimated, IHME study suggests
More than 1.2 million people died from malaria worldwide in 2010, twice the number found in the most recent comprehensive study of the disease.
Pharma Industry 03/02/2012
Merck & Co enjoys healthy quarter but expects flat sales in 2012
Turnover from the HIV drug Isentress (raltegravir) reached $387 million, up 24%.
World Policy 03/02/2012
WHO to issue guidance on hormonal contraceptives and HIV
New findings in 2011 imply a possible increase in HIV infection among women at risk of HIV who use hormonal contraception, or increased transmission to an un-infected partner when a woman is living with HIV and using hormonal contraceptives.
Tuberculosis & Malaria 03/02/2012
Inaccurate TB blood tests commonplace in many TB high-burden countries
17 of 22 highest TB burden countries have these assays on the market.
Access to treatment 02/02/2012
Key generic manufacturer Emcure joins the Medicines Patent Pool
Emcure will be able to manufacture several products licensed to the Pool by Gilead Sciences.
Treatment 02/02/2012
Isentress, Intelence, Prezista regimen goes the distance for HIV treatment veterans
In treatment-experienced patients, an antiretroviral regimen containing raltegravir, etravirine and darunavir/ritonavir shows high efficacy, with a good safety profile.


